The aim of the award procedure is the conclusion of a temporary service contract for consulting services, through which SPRIND is to be supported during the 2nd and optionally 3rd stage of the challenge "A quantum leap for new antiviral agents". The focus of the consulting services is: (1) advice and support for the teams participating in the Challenge, (2) support of SPRIND during the Challenge and (3) support of the Challenge Jury and (4) support with other questions related to the Challenge.

SPRIND GmbH - Federal Agency for Leap Innovations (SPRIND) is currently conducting a challenge on the topic "A quantum leap for new antiviral agents". The aim of this challenge is to create innovations that provide new antiviral agents. In the course of this, SPRIND intends to conclude a temporary service contract for consulting services, through which SPRIND is to be supported during the 2nd and optionally 3rd stage of the challenge "A quantum leap for new antiviral agents". The focus of the consulting services is: (1) advice and support for the teams participating in the Challenge, (2) support of SPRIND during the Challenge and (3) support of the Challenge Jury and (4) support with other questions related to the Challenge. The SPRIND expects an average of 30 working hours per week in both the 2nd and 3rd challenge levels. The actual consulting effort is directly dependent on the number of teams participating in the respective level and the required consulting/support needs of the individual teams and may vary during the term of the contract. In addition, workshops with SPRIND and the participating teams as well as on-site visits of the teams are planned. Further details can be found in Appendix 1 - Service description from 12.09.2022. Performance requires demonstrable experience in the areas of a) technical and regulatory advice on innovative technologies (e.g. ATMPs) or advice on the selection of contractors (CMO, CRO, CMC), b) development of regulatory strategies (for various regulatory markets), c) advice on or support in the development of antiviral therapeutics and d) support in applying for clinical trials and other approvals.

SPRIND has the unilateral option to extend the term of the service contract once by another year until 31.10.2024.